AlphaFold gets an upgrade (and a Nobel)

IF 58.7 1区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Nature Medicine Pub Date : 2024-12-13 DOI:10.1038/s41591-024-03392-x

Karen O’Leary

引用次数: 0

查看原文本刊更多论文

AlphaFold获得升级（和诺贝尔奖）

AlphaFold是由b谷歌DeepMind开发的预测蛋白质结构的人工智能工具，它标志着蛋白质建模和药物发现的一个分水岭。AlphaFold 2能够以非常高的精度预测蛋白质的三维结构，接近于需要数月至数年时间才能获得的实验结果。最新的版本AlphaFold 3（5月发布）更进了一步，比它的前身实现了更高的准确性，同时功能也得到了扩展。AlphaFold 3不仅可以预测蛋白质的结构，还可以预测含有蛋白质和其他结构的复合物的结构，如核酸和小分子。事实上，作者预计，由于深度学习和实验方法的进步，建模能力将继续提高。为了认识到这些进步的重要性，诺贝尔化学奖的一半授予了领导AlphaFold开发的John Jumper和Demis Hassabis（另一半授予了华盛顿大学的David Baker，以表彰他在计算蛋白质设计方面的成就）。原始参考文献：Nature 630, 493-500 (2024)；诺贝尔奖网站https://go.nature.com/4evrnLN（2024年11月13日）

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Medicine 医学-生化与分子生物学

CiteScore

100.90

自引率

0.70%

发文量

525

审稿时长

1 months

期刊介绍： Nature Medicine is a monthly journal publishing original peer-reviewed research in all areas of medicine. The publication focuses on originality, timeliness, interdisciplinary interest, and the impact on improving human health. In addition to research articles, Nature Medicine also publishes commissioned content such as News, Reviews, and Perspectives. This content aims to provide context for the latest advances in translational and clinical research, reaching a wide audience of M.D. and Ph.D. readers. All editorial decisions for the journal are made by a team of full-time professional editors. Nature Medicine consider all types of clinical research, including: -Case-reports and small case series -Clinical trials, whether phase 1, 2, 3 or 4 -Observational studies -Meta-analyses -Biomarker studies -Public and global health studies Nature Medicine is also committed to facilitating communication between translational and clinical researchers. As such, we consider “hybrid” studies with preclinical and translational findings reported alongside data from clinical studies.